Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Invested Capital (2020 - 2025)

Tango Therapeutics has reported Invested Capital over the past 6 years, most recently at $346.2 million for Q4 2025.

  • Quarterly results put Invested Capital at $346.2 million for Q4 2025, up 73.51% from a year ago — trailing twelve months through Dec 2025 was $346.2 million (up 73.51% YoY), and the annual figure for FY2025 was $346.2 million, up 73.51%.
  • Invested Capital for Q4 2025 was $346.2 million at Tango Therapeutics, up from $160.0 million in the prior quarter.
  • Over the last five years, Invested Capital for TNGX hit a ceiling of $365.4 million in Q3 2021 and a floor of $54.9 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $248.6 million (2022), compared with a mean of $234.2 million.
  • Biggest five-year swings in Invested Capital: surged 793.13% in 2021 and later crashed 45.51% in 2025.
  • Tango Therapeutics' Invested Capital stood at $344.7 million in 2021, then fell by 27.64% to $249.5 million in 2022, then rose by 1.46% to $253.1 million in 2023, then decreased by 21.17% to $199.5 million in 2024, then soared by 73.51% to $346.2 million in 2025.
  • The last three reported values for Invested Capital were $346.2 million (Q4 2025), $160.0 million (Q3 2025), and $135.0 million (Q2 2025) per Business Quant data.